Why Novartis lost its treatment dispute with Teva

In a patent revocation and infringement counterclaim action between Teva and Novartis, His Honour Judge Richard Hacon found, in a decision handed down on November 10 2022, lack of inventive step with respect to two Novartis formulation patents ( EP 2,964,202 and EP 3,124,018)

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Big Pharma

US life sciences damages averaged $33.5m between 2019-2025

18 June 2026 Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study.

Big Pharma

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

15 April 2026 The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.

Big Pharma

Part II: The race to replace semaglutide heats up

23 March 2026 With Novo Nordisk's core semaglutide patent expired in India last week, the company that built one of the most successful drugs in pharmaceutical history is already fighting on a new front. So what comes next?

More features

Pfizer’s US Paxlovid patent fight turns on a single error

Novo secures website blocking to tackle fake weight-loss drugs

GLP-1 patents and Africa: The COVID-19 lessons we still have not learned

‘Blatant imitation’: Indian court blocks copycat pharma branding

US life sciences damages averaged $33.5m between 2019-2025

Quantum and photonics tech licensing expert joins EIP

Amgen and subsidiary dealt $20m blow over rodent antibody tech

Moderna: BioNTech is claiming work ‘it never did’

Why Novartis lost its treatment dispute with Teva

More on this story

Editor's picks

Editor's picks

More features